Report
Eli Lilly's obesity drug combo reportedly boosted weight loss in a mid-stage trial
CNBC reports that Lilly plans to begin Phase 3 trials of the regimen, which adds its amylin drug eloralintide to tirzepatide, at the end of 2026.
TLDR
CNBC reports that Eli Lilly said its combination obesity regimen boosted weight loss in a mid-stage trial. The regimen adds Lilly's amylin drug eloralintide to tirzepatide, and the company plans to begin Phase 3 trials at the end of 2026.
Combined views
51.9K
2 Sources, first seen 1d ago
35 likes